649 results about "Therapeutic strategy" patented technology

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention belongs to the technical field of genetic engineering and biological medicine, and particularly discloses a cascade response type nano-particle with a microenvironment remodeling function and a preparation method and application of the cascade response type nano-particle. The nanoparticle provided by the invention adopts a bionic hybrid membrane engineering strategy: an inner core is formed by loading an exosome inhibitor on a nano material, and the surface is covalently coupled with M2 type macrophage specific targeting peptide; the outer layer coats a macrophage membrane and active oxygen response type liposome composite membrane layer through a co-extrusion technology, and is loaded with a TLR agonist. Animal experiments show that after being injected through caudal vein, the nano-particles are enriched at a tumor site in a targeted manner through homing receptors such as membrane surface integrin alpha4beta1 and the like, and outer membrane cracking is triggered in a high-ROS tumor microenvironment, so that space-time controlled release of a TLR agonist and targeted phagocytosis of an exosome inhibitor by macrophages guided by a targeted peptide are realized. The anti-tumor synergistic effect is achieved through multiple regulation and control mechanisms, and an effective treatment strategy is provided for tumor immunotherapy.

The invention belongs to the field of biological medicines, and discloses an application of Akkermansia muciniphila or an extracellular vesicle of the Akkermansia muciniphila in preparation of a medicine for alleviating the ischemic necrosis of the alcoholic femoral head. Based on the pathogenesis characteristics of the AIONFH, the Akk bacteria and the extracellular vesicles thereof are used for treating the AIONFH for the first time, the molecular mechanism of the Akk bacteria and the extracellular vesicles thereof for regulating and controlling the intestinal tract-skeleton axis function, inhibiting bone cell apoptosis and improving the bone trabecula microstructure is deeply researched, the anti-pressure ability of bone tissue is improved, and the research blank in the field is filled. Compared with a traditional treatment method, the osteonecrosis pathological change is improved through a single way, and a novel multi-target treatment strategy is provided from multiple aspects of regulating inflammatory response, recovering bone metabolism balance, promoting intraosseous blood supply and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to an iron-based nano material, a preparation method and application of the iron-based nano material in preparation of medicines for treating breast cancer. The iron-based nano material is formed by loading a ferroptosis inducer on a nano carrier; the nano carrier is an iron-based metal organic framework material Fe-MOF (Metal Organic Framework). A product FEH for treating breast cancer is obtained based on coupling of the iron-based nano-material provided by the invention with a targeted drug such as trastuzumab. The FEH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of trastuzumab and ferroptosis combined anti-tumor. As a safe and effective tumor treatment strategy, the EFH has huge clinical transformation potential.

The invention relates to the technical field of genetic engineering, in particular to a long-chain RNALnc012227 for inhibiting transmission of salmonella enteritidis ovary and application of the long-chain RNALnc012227 in prevention and control of salmonella enteritidis infection. The invention relates to a long-chain RNA (Ribonucleic Acid) Lnc012227 for inhibiting transmission of salmonella enteritidis ovary. The Lnc012227 provided by the invention can be used for indirectly regulating the expression of MAP3K8, activating NF-kappa B and MAPK signal channels and enhancing the inflammatory response of a host, so that S.Enteridis infection is controlled. The discovery not only provides a new understanding of molecular level for understanding the infection mechanism of salmonella in the duck body, but also provides a potential target spot for developing a new treatment strategy, and is helpful for reducing egg-laying duck ovarian infection and duck egg pollution caused by salmonella.

The invention provides a follow-up visit consultation system for chronic pain patients, and relates to the technical field of intelligent medical treatment, and the system comprises a data collection unit which is used for obtaining subjective pain description data, real-time physiological monitoring data and historical diagnosis and treatment data of a patient; the prediction analysis unit is used for performing pain deterioration risk prediction based on the multi-source data and an artificial intelligence model, and outputting a prediction result containing a risk level and individualized pathological features; and the dynamic intervention unit is used for generating dynamic treatment suggestions according to the prediction result, pushing the dynamic treatment suggestions to the doctor and the patient, and receiving execution feedback data of the patient so as to perform closed-loop optimization on the treatment strategy. According to the technical scheme, the subjective pain description, the real-time physiological monitoring data and the historical diagnosis and treatment records of the patient are obtained at the same time, the integrity of the data is improved through the comprehensive collection mode of multi-source data, the accuracy and timeliness of information are ensured, and the problems of subjective deviation and inaccuracy caused by the fact that follow-up visit depends on memory of the patient are solved.

The present invention relates to a use of THBS1 as a novel combination drug target that can overcome drug resistance of a targeted anticancer agent. A THBS1 inhibitor according to the present invention inhibits the drug resistance of a target anticancer agent and thus increases an anticancer effect when administered in combination with a target anticancer agent. Accordingly, the present invention can overcome resistance to a targeted anticancer agent and increase a treatment success rate of anticancer drugs for cancer patients, thereby suggesting new possibilities for treatment strategies using targeted anticancer drugs and contributing to the realization of precision medicine.

The invention discloses an application of a small molecule compound SFII in preparation of drugs for resisting pyroptosis and GSDMD inhibitors with pyroptosis resisting activity. The small molecule compound Scutellaria flavone II (SII) extracted from Scutellaria baicalensis roots plays an important role in preparation of drugs for inhibiting pyroptosis inflammation so as to prevent or treat atherosclerosis. Experiments prove that the active pharmaceutical ingredient SFII has a definite effect on promoting atherosclerosis by virtue of Gasdermin D and GSDMD mediated macrophage pyroptosis, is convenient to obtain, can be used for preparing drugs for inhibiting GSDMD protein activity to resist pyroptosis and exerting an anti-inflammatory effect so as to prevent or treat atherosclerosis, and has a remarkable effect. The small molecule compound SFII provides a new treatment strategy for atherosclerosis, and has a wide application prospect.

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention relates to the technical field of biomedicine, in particular to a liver cancer molecular subtype typing and prognosis model construction method based on glycometabolism and lactic acid metabolism related genes and application thereof. According to the invention, the typing and prognosis model of liver cancer subtypes is constructed for the first time on the basis of a coordinated regulation network of a glycometabolism gene and a lactic acid metabolism gene, the constructed liver cancer subtype subtypes comprise Cluster1 and Cluster2, and the total survival rates of different subtypes have significant difference; the clinical characteristics T.stage and TNM.stage of different subtypes are obviously different from each other; 12 kinds of immune cells have significant differences among different subtypes; iPS immune scores of different subtypes are significantly different; the TIDE scores of different subtypes have significant score differences; the genes with the highest mutation frequency in different subtypes comprise TP53, CTNNB1 and TTN. CLM scores of the prognosis model constructed on the basis of the collaborative regulation network of the glycometabolism genes and the lactic acid metabolism genes have no significant difference in different patient states; the 17 immune cells have significant differences between high and low risk groups. And a new way is provided for individualized treatment strategy formulation and survival outcome improvement of HCC.

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing and / or treating biliary atresia. The new application of ganoderic acid A in preparation of drugs for preventing and / or treating biliary atresia is found for the first time. The method comprises the following steps: within 24 hours after a BALB / c newborn mouse is born, inducing the formation of BA by intraperitoneal injection of RRV, and from the second day after intraperitoneal injection of RRV, carrying out intraperitoneal injection of Ganoderic Acid A on the mouse every day until the twelfth day, it can be observed that the survival time of BA mice treated by the Ganoderma Acid A is prolonged, the weight loss is obviously improved, the jaundice symptom is relieved, the liver function index is obviously improved, the infiltration number of inflammatory cells around the intrahepatic bile duct is obviously reduced, and the liver bile duct injury is relieved. The invention provides a new potential target and a treatment strategy for treatment of BA, and has potential clinical treatment significance.

The invention relates to the technical field of biomedicine, in particular to siRNA (small interfering ribonucleic acid) for interfering Tc11a gene expression, a core-shell type nano particle as well as a preparation method and application of the core-shell type nano particle. The invention relates to a method for treating type I diabetes mellitus by using core-shell nanoparticles (siTc11a NPs) of a targeted mouse Tc11a gene on an NOD model mouse, and provides a preparation method of the nanoparticles. The preparation method comprises the following steps: mixing siRNA (small interfering ribonucleic acid) interfering with a Tc11a gene with cationic liposome G0-C14 to obtain a complex; mixing the complex with a polylactic acid-glycolic acid copolymer to obtain a core substance; and mixing the core substance with the lipid polymer to obtain the core-shell nanoparticles. The invention provides a treatment strategy for treating the type I diabetes mellitus through targeted Tcl1a gene regulation and control.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The invention discloses an application of a pyroptosis inhibitor in preparation of a product for treating biliary atresia, the pyroptosis inhibitor 2-bromohexadecanoic acid has a certain treatment effect on biliary atresia mice, can significantly prolong the survival time of the mice, improve jaundice, improve the liver function of the mice, reduce the infiltration quantity of inflammatory cells around intrahepatic bile ducts, and can be used for treating the biliary atresia. A new potential target and a treatment strategy are provided for treatment of biliary atresia.

The invention belongs to the technical field of biological medicines, and particularly relates to a ferrozirconium bimetallic nano-material, a preparation method and application of the ferrozirconium bimetallic nano-material in preparation of medicines for treating breast cancer. The ferrozirconium bimetallic nano material is formed by loading a CDK4 / 6 inhibitor on a nano carrier; wherein the nano carrier is an organic framework material Zr-Fe MOF containing double metals of Zr and Fe, and the CDK4 / 6 inhibitor is preferably ribociclib. A product ZFRH for treating breast cancer is obtained based on coupling of the ferrozirconium bimetallic nano-material provided by the invention with a targeted drug such as trastuzumab. The ZFRH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of combined anti-tumor of trastuzumab and a CDK4 / 6 inhibitor. As a safe and effective tumor treatment strategy, the ZFRH has huge clinical transformation potential.

The invention relates to the field of biological medicine, and discloses application of LPC, PC and AA in children sepsis diagnosis and prognosis product development. According to the invention, a high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS) technology is used, plasma samples of a child sepsis patient and a healthy control group are compared, the relationship between lipidome change and pSOFA score is analyzed, and specific lipid molecules closely related to disease severity and prognosis are identified. According to the invention, the following lipid molecules are highlighted as key biomarkers: lysophosphatidylcholine (LPC), phosphatidylcholine (PC) and arachidonic acid (AA). The change of the lipid molecules is closely related to the physiological state of a child sepsis patient, and the lipid molecules can be used for early diagnosis and evaluation of the state of the child sepsis, so that the treatment effect and the accuracy of prognosis evaluation are improved, and a new treatment strategy and a new management method are provided for clinic.

The invention discloses an application of intestinal bacteria in an ulcerative colitis prediction technology, and belongs to the technical field of biology, and the intestinal bacteria are Alistipes finegoldii; the method comprises the following steps: detecting the relative abundance of Alistipes finegii in an excrement sample of a patient, and using the low relative abundance of Alistipes finegii to predict the disease activity of ulcerative colitis; according to the application disclosed by the invention, not only is the association between the Alistipes finegili and the UC disease activity verified, but also the potential action mechanism of the Alistipes finegili is further explored. By means of 16s amplicon sequencing and transcriptomics combined analysis, it is found that the Alistipes finegili plays an anti-inflammatory role through an Hsp90 / AMPK / ACC signal channel, and the intestinal barrier function is maintained. The invention verifies that a new view angle is provided for the effect of the Alistipes finegili in the UC pathogenesis, and provides a theoretical basis for developing a treatment strategy based on the strain.

The invention discloses a method for identifying early-stage diabetic patients based on physiological and biochemical indexes. The method comprises the following steps: collecting data; analyzing and preprocessing data; a BP neural network model is adopted, and the model comprises an input layer, six hidden layers and an output layer; model training: dividing the source data into a training set and a test set according to the ratio of 7: 3 for model training, the training round epoch is 70, the batch size is 16, and in the training process, 10% of the training data is used as a verification set for evaluating the performance; and evaluating a result. By comprehensively considering the multi-dimensional clinical data of the patient, the classification model capable of accurately identifying the risk of the early diabetes mellitus of the individual is developed, and the accuracy and reliability of early diabetes mellitus identification are improved; and a doctor can be assisted to formulate personalized prevention and treatment strategies through the identification result of the model.

The invention belongs to the technical field of biological medicines, and particularly relates to placenta targeting peptide plCSA-BP modified tetrahedral framework nucleic acid as well as a preparation method and application thereof. The placenta targeting peptide plCSA-BP is creatively combined with tFNAs to form a tFNAs / plCSA-BP compound, the compound has excellent placenta targeting property and can effectively improve the function of placenta trophoblasts, so that the treatment effect of preeclampsia is remarkably improved, a new treatment strategy is provided for the placenta diseases in the gestation period, and the placenta targeting peptide plCSA-BP has a good application prospect. The application prospect of the nano material in placental disease treatment is expanded.

Methods for testing the effects of therapeutic compound candidates on a phenotypic organoid model is provided. Such a method includes steps of generating the phenotypic organoid model on a high throughput screening platform, treating the organoid with a therapeutic compound candidate, and testing one or more effects resulting from treatment with each of the therapeutic compound candidates. The testing method that has led to identification of a method for treating or preventing cysts is provided. That method may include contacting a population of cells with an inotrope, wherein the inotrope prevents cyst formation, shrinks existing cysts, or both. That method may be used to treat cystogenic diseases or conditions such as Polycystic Kidney Disease (PKD).

The present invention belongs to the field of bioelectrode technology, and specifically relates to an injectable soft bioelectrode hydrogel and its preparation method and application. The preparation method includes preparing an E-A complex and preparing a hydrogel. The hydrogel of the present invention is used to prepare an injectable soft bioelectrode, and the hydrogel is directly injected into the target tissue site through a needle to form a flexible and well-adhesive electrical stimulation interface, which significantly improves the accuracy and stability of electrical stimulation. The hydrogel composition principle and preparation method make it easier to regulate and micro-precisely inject according to different human body parts or clinical needs. Implanting the hydrogel into acupuncture points or other specific tissue sites and applying electrical stimulation can effectively avoid local tissue trauma and immune overreaction caused by traditional hard electrodes. For example, for pancreatic cancer, the electrode of the present invention can achieve more controllable and continuous electrical stimulation, and has the potential to regulate local immune response and inflammation levels, providing a safer and more cost-effective new treatment strategy for clinical diagnosis and treatment.

The invention discloses an acoustic catalyst as well as a preparation method and application thereof, and belongs to the technical field of catalysts and drug therapy. NJU-319 is selected as an acoustic catalyst, NJU-319Pt is synthesized from a porphyrinyl linker (TAPP) and a hexaphenyl triphenyl unit (HFPTP) under a solvothermal condition, and the H2 generation efficiency of NJU-319Pt can be further improved. After intraperitoneal injection, the nano-drug NJU-319Pt catalyzes H2O to be reduced into H2 under ultrasonic irradiation, and meanwhile lactic acid is oxidized into pyruvic acid. The action mechanism comprises: removing ROS and relieving oxidative stress; by inhibiting an NF-kappa B pathway, the transformation of macrophages from M1 phenotype to M2 phenotype is promoted, and inflammation is reduced; mitochondrial membrane potential is reduced, EMs cell apoptosis is induced, and focus growth is inhibited. The research provides a brand new EMs treatment strategy, combines acoustic catalysis H2 generation with lactic acid oxidation, and provides a new direction for EMs treatment research.

The invention provides Edwardsiella tarda bacteriophage vBEtaS6 and prevention and treatment application, the Edwardsiella tarda bacteriophage vBEtaS6 is preserved in China Center for Type Culture Collection (CCTCC) on April 27, 2025, the preservation number is CCTCC NO: M 2025899, the preservation address is Wuhan University, Wuchang District, Wuhan City, Hubei Province, the postal code is 430072, and the Edwardsiella tarda bacteriophage vBEtaS6 is named as Edwardsiella tarda phage. According to the invention, the treatment strategy of edwardsiella tarda is enriched, and a foundation is laid for inhibiting the outbreak of bacterial diseases in crocodile culture.

The invention discloses a black phosphorus hydrogel microneedle patch loaded with trained mesenchymal stem cells as well as a preparation method and application of the black phosphorus hydrogel microneedle patch, and belongs to the technical field of biological medicines. The micro-needle patch comprises a hydrogel substrate layer loaded with black phosphorus nanosheets and a hydrogel needle tip part for packaging the stem cells. The mesenchymal stem cells are subjected to combined domestication with low oxygen and high active oxygen, so that the anti-oxidative stress, anti-inflammatory and angiogenesis promoting capabilities of the mesenchymal stem cells are remarkably enhanced. After the patch is subcutaneously delivered, the black phosphorus component can efficiently remove bacteria and reduce drug resistance; after being domesticated, the stem cells can adapt to the immune microenvironment of the wound surface, and the immune regulation, inflammation inhibition and tissue regeneration promotion are synergistically realized by continuously releasing anti-inflammatory and angiogenesis promoting factors, so that the refractory wound surface caused by immune disorders such as systemic lupus erythematosus (SLE) and the like is effectively treated. The invention provides an innovative treatment strategy for chronic inflammatory wound healing.

The invention belongs to the technical field of protein polypeptides, and particularly relates to a polypeptide targeting BRCA2 protein, application of the polypeptide and a medicine for treating prostatic cancer. The amino acid sequence of the polypeptide is shown as SEQ ID NO.1, the polypeptide has high binding capacity with BRCA2 protein, cell proliferation and tumor growth can be effectively inhibited when the polypeptide is delivered to prostatic cancer, and meanwhile the polypeptide has the capacity of degrading BRCA2 in a targeted mode. The combined application of the polypeptide and the PARP inhibitor can enhance the sensitivity of prostate cancer cells to the PARP inhibitor. Therefore, the polypeptide can be applied to preparation of a medicine for treating metastatic castration-resistant prostate cancer or preparation of a reagent for degrading the BRCA2 protein. The BRCA2 targeting PROTAC medicine can provide a new treatment strategy for prostatic cancer treatment, and the PARP targeting inhibitor is combined to provide a PARP inhibitor synthesis lethal treatment effect for metastatic castration resistant prostatic cancer patients.

The invention discloses application of a TIMM10 gene as a target spot in resisting influenza A virus, and belongs to the technical field of biological medicine. Specifically, TIMM10 gene knock-down is carried out on A549 cells, and it is found that in the cells with knocked-down TIMM10, expression of main protein hemagglutinin and nucleoprotein of influenza viruses is remarkably improved, and virus RNA and virus titer in supernate are also remarkably increased; overexpression of TIMM10 in A549 cells inhibits replication and infectivity of IAV in the cells. A further in-vivo experiment is carried out through a TIMM10 whole body knockout heterozygote mouse, and a result shows that the lung of the TIMM10 heterozygote mouse shows more serious pulmonary infection, including pulmonary hemorrhage and increased inflammatory cell infiltration. Based on the effect of TIMM10 in the influenza virus infection process, the invention provides a new therapeutic target, and provides a new thought and direction for developing a therapeutic strategy for IAV in the future.